{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:49:22Z","timestamp":1781642962514,"version":"3.54.5"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Oral and Dental Research Trust"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Intervention in the pre-arthritis phase of RA could prevent or delay the onset of disease. The primary aim of this study was to explore perspectives of being at risk and potential preventive interventions among individuals at risk of developing RA and to identify factors influencing their engagement with prevention. A secondary aim, established during the analytical process, was to understand and compare different approaches to health-related behaviours related to prevention of RA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Anti-CCP-positive (CCP+) at-risk individuals with musculoskeletal symptoms but no synovitis participated in semi-structured interviews. Data were analysed using reflexive thematic analysis, followed by a secondary ideal-type analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Nineteen CCP+ at-risk individuals (10 women; age range 35\u201370\u00a0years) participated. Three overarching themes were identified: being CCP+ at risk; aiming to prevent RA; and influencers of engagement. Participants described distress related to symptoms and uncertainty about disease progression. Many participants had concerns about medication side effects. In contrast, most participants expressed willingness to make lifestyle changes with the aim of preventing RA. Engagement with preventive measures was influenced by symptom severity, personal risk level, co-morbidities, experiences of taking other medications\/supplements, knowledge of RA, risk factors and medications, and perceived effort. Three types of participants were identified from the data: proactive preventers, change considerers and fearful avoiders. Overall orientation to health behaviours also impacted the attitude towards preventing RA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Findings could inform recruitment and retention in RA prevention research and promote uptake of preventive interventions in clinical practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkae023","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T23:03:28Z","timestamp":1709075008000},"source":"Crossref","is-referenced-by-count":2,"title":["\u2018What is my risk really?\u2019: a qualitative exploration of preventive interventions among individuals at risk of rheumatoid arthritis"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4207-2809","authenticated-orcid":false,"given":"Lara S","family":"Chapman","sequence":"first","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J","family":"Siddle","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Serban","sequence":"additional","affiliation":[{"name":"School of Medicine, Dentistry and Nursing, University of Glasgow , Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7945-6582","authenticated-orcid":false,"given":"Kulveer","family":"Mankia","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds, UK"},{"name":"NIHR Leeds Biomedical Research Centre , Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3640-853X","authenticated-orcid":false,"given":"Christopher M","family":"Rooney","sequence":"additional","affiliation":[{"name":"Leeds Institute of Medical Research, University of Leeds , Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhain","family":"Mustufvi","sequence":"additional","affiliation":[{"name":"School of Dentistry, University of Leeds , Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Pini","sequence":"additional","affiliation":[{"name":"Leeds Institute of Health Sciences, University of Leeds , Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6362-9824","authenticated-orcid":false,"given":"Karen","family":"Vinall-Collier","sequence":"additional","affiliation":[{"name":"School of Dentistry, University of Leeds , Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"2024031419034351200_rkae023-B1","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/art.39603","article-title":"Preclinical rheumatoid arthritis: progress toward prevention","volume":"68","author":"Mankia","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"2024031419034351200_rkae023-B2","first-page":"86","article-title":"OP0130 Abatacept in individuals at risk of developing rheumatoid arthritis: results from the arthritis prevention in the pre-clinical phase of RA with abatacept (APIPPRA) trial","volume":"82","author":"Cope","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024031419034351200_rkae023-B3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","article-title":"Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study","volume":"78","author":"Gerlag","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024031419034351200_rkae023-B4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(22)01193-X","article-title":"Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial","volume":"400","author":"Krijbolder","year":"2022","journal-title":"Lancet"},{"key":"2024031419034351200_rkae023-B5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s13063-019-3403-7","article-title":"Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol","volume":"20","author":"Al-Laith","year":"2019","journal-title":"Trials"},{"key":"2024031419034351200_rkae023-B6"},{"key":"2024031419034351200_rkae023-B7","doi-asserted-by":"crossref","first-page":"e001768","DOI":"10.1136\/rmdopen-2021-001768","article-title":"A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis","volume":"7","author":"Mankia","year":"2021","journal-title":"RMD Open"},{"key":"2024031419034351200_rkae023-B8","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/rheumatology\/keaa792","article-title":"Perturbations of the gut microbiome in anti-CCP positive individuals at risk of developing rheumatoid arthritis","volume":"60","author":"Rooney","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024031419034351200_rkae023-B9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41579-021-00667-9","article-title":"Microbiome-based therapeutics","volume":"20","author":"Sorbara","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"2024031419034351200_rkae023-B10","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/01.CIR.96.4.1089","article-title":"Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke","volume":"96","author":"Lightwood","year":"1997","journal-title":"Circulation"},{"key":"2024031419034351200_rkae023-B11","first-page":"30","article-title":"The effects of oral health on systemic health","volume":"65","author":"Kane","year":"2017","journal-title":"Gen Dent"},{"key":"2024031419034351200_rkae023-B12","first-page":"397","article-title":"Beneficial health effects of modest weight loss","volume":"16","author":"Goldstein","year":"1992","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2024031419034351200_rkae023-B13","doi-asserted-by":"crossref","first-page":"e001592","DOI":"10.1136\/rmdopen-2021-001592","article-title":"How to enhance recruitment of individuals at risk of rheumatoid arthritis into trials aimed at prevention: understanding the barriers and facilitators","volume":"7","author":"van Boheemen","year":"2021","journal-title":"RMD Open"},{"key":"2024031419034351200_rkae023-B14","doi-asserted-by":"crossref","first-page":"e001591","DOI":"10.1136\/rmdopen-2021-001591","article-title":"Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial","volume":"7","author":"van Boheemen","year":"2021","journal-title":"RMD Open"},{"key":"2024031419034351200_rkae023-B15","doi-asserted-by":"crossref","first-page":"883287","DOI":"10.3389\/fimmu.2022.883287","article-title":"Perspectives of at-risk individuals on preventive intervention for rheumatoid arthritis: a mini review","volume":"13","author":"Falahee","year":"2022","journal-title":"Front Immunol"},{"key":"2024031419034351200_rkae023-B16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/annrheumdis-2021-221160","article-title":"Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies","volume":"81","author":"Siddle","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024031419034351200_rkae023-B17","doi-asserted-by":"crossref","first-page":"e003099","DOI":"10.1136\/rmdopen-2023-003099","article-title":"\u2018It surprised me a lot that there is a link\u2019: a qualitative study of the acceptability of periodontal treatment for individuals at risk of rheumatoid arthritis","volume":"9","author":"Chapman","year":"2023","journal-title":"RMD Open"},{"key":"2024031419034351200_rkae023-B18","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/annrheumdis-2021-220884","article-title":"EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis","volume":"80","author":"Mankia","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024031419034351200_rkae023-B19","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/rheumatology\/keac397","article-title":"Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania","volume":"62","author":"Simons","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2024031419034351200_rkae023-B20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1186\/s13063-021-05682-y","article-title":"The effect of a multidisciplinary lifestyle program for patients with rheumatoid arthritis, an increased risk for rheumatoid arthritis or with metabolic syndrome-associated osteoarthritis: the \u201cPlants for Joints\u201d randomized controlled trial protocol","volume":"22","author":"Walrabenstein","year":"2021","journal-title":"Trials"},{"key":"2024031419034351200_rkae023-B21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"key":"2024031419034351200_rkae023-B22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1035719X211058251","article-title":"Thematic analysis: a practical guide","volume":"22","author":"Forbes","year":"2022","journal-title":"Eval J Australas"},{"key":"2024031419034351200_rkae023-B23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/978-981-10-5251-4_103","volume-title":"Handbook of research methods in health social sciences","author":"Braun","year":"2019"},{"key":"2024031419034351200_rkae023-B24","doi-asserted-by":"crossref","first-page":"160940692211006","DOI":"10.1177\/16094069221100633","article-title":"Developing typologies in qualitative research: the use of ideal-type analysis","volume":"21","author":"Stapley","year":"2022","journal-title":"Int J Qual Methods"},{"key":"2024031419034351200_rkae023-B25","doi-asserted-by":"crossref","first-page":"e055464","DOI":"10.1136\/bmjopen-2021-055464","article-title":"What the public in England know about antibiotic use and resistance in 2020: a face-to-face questionnaire survey","volume":"12","author":"McNulty","year":"2022","journal-title":"BMJ Open"},{"key":"2024031419034351200_rkae023-B26","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/cdoe.12766","article-title":"Using behaviour change science to deliver oral health practice: a commentary","volume":"51","author":"Asimakopoulou","year":"2023","journal-title":"Community Dent Oral Epidemiol"},{"key":"2024031419034351200_rkae023-B27","author":"Kitsaras"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkae023\/56810496\/rkae023.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/8\/2\/rkae023\/56974261\/rkae023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/8\/2\/rkae023\/56974261\/rkae023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T19:25:58Z","timestamp":1710444358000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkae023\/7616985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3,14]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkae023","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2024,1,1]]},"article-number":"rkae023"}}